Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Nov 15;17(22):6958-62.
doi: 10.1158/1078-0432.CCR-11-1595. Epub 2011 Sep 7.

Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma

Evan J Lipson  1 , Charles G Drake
Affiliations
Review

Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma

Evan J Lipson et al. Clin Cancer Res. .

Abstract

Ipilimumab (MDX-010, Yervoy; Bristol-Myers Squibb), a fully human monoclonal antibody against CTL antigen 4 (CTLA-4), was recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of metastatic melanoma. In both early- and late-phase trials, ipilimumab has shown consistent activity against melanoma. For example, in a randomized phase III trial that enrolled patients with previously treated metastatic disease, ipilimumab, with or without a peptide vaccine, improved overall survival: Median overall survival was 10.1 and 10.0 months in the ipilimumab and ipilimumab plus vaccine arms, respectively, versus 6.4 months in the vaccine-alone group (hazard ratio, 0.68; P ≤ 0.003). Serious (grade 3-5) immune-related adverse events occurred in 10% to 15% of patients. Thus, although it provides a clear survival benefit, ipilimumab administration requires careful patient monitoring and sometimes necessitates treatment with immune-suppressive therapy. Here, we review the mechanism of action, preclinical data, and multiple clinical trials that led to FDA approval of ipilimumab for metastatic melanoma.

PubMed Disclaimer

Figures

Figure 1
Figure 1
A, melanoma cells express proteins, such as gp100, MART-1, and tyrosinase, that may be processed and presented by antigen-presenting cells. T-cell recognition of peptide antigens derived from these proteins can potentially drive an antitumor immune response. For such tumor-directed T cells to become activated, 2 signals are required. The first signal (signal 1) occurs when the peptide antigen is recognized by the T-cell receptor on antigen-specific T cells. This recognition is exquisitely specific. However, for full T-cell activation, proliferation, and effector function, a second signal (signal 2) is needed. This signal is typically mediated by the interaction between costimulatory molecules such as B7.1 and B7.2 on antigen-presenting cells and CD28 on T cells. In reality, the situation is more complex, and signal 2 is derived from the integration of several positive and negative events. B, under certain conditions, T cells upregulate the cell surface molecule CTLA-4, which binds to B7.1 and B7.2 with greater affinity than does CD28. This series of events effectively hijacks signal 2, resulting in a situation in which specific T cells cannot be fully activated. C, ipilimumab (and other anti-CTLA-4 antibodies) bind to CTLA-4 on the cell surface, effectively blocking the interaction between CTLA-4 and B7.1/B7.2. This leads to interruption of the negative signal mediated by CTLA-4, the resumption of signal 2, and a relative restoration of T-cell activation.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Brunet JF, Denizot F, Luciani MF, Roux-Dosseto M, Suzan M, Mattei MG, et al. A new member of the immunoglobulin superfamily—CTLA-4. Nature. 1987;328:267–70. - PubMed
    1. Thompson CB, Allison JP. The emerging role of CTLA-4 as an immune attenuator. Immunity. 1997;7:445–50. - PubMed
    1. Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee KP, et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science. 1995;270:985–8. - PubMed
    1. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. 1995;3:541–7. - PubMed
    1. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996;271:1734–6. - PubMed

Publication types

MeSH terms